| scholarly article | Q13442814 |
| P50 | author | Sakae Tanaka | Q39065998 |
| P2093 | author name string | Matsumoto K | |
| Yamamoto T | |||
| Kobayashi N | |||
| Naito A | |||
| Inoue J | |||
| Kadono Y | |||
| P2860 | cites work | The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway | Q22009096 |
| ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway | Q22010492 | ||
| Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene | Q22299417 | ||
| Involvement of CRAF1, a relative of TRAF, in CD40 signaling | Q24306746 | ||
| Anatomy of TRAF2. Distinct domains for nuclear factor-kappaB activation and association with tumor necrosis factor signaling proteins | Q24311703 | ||
| A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor | Q24318280 | ||
| NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway | Q24321670 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain | Q24604330 | ||
| TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling | Q24634187 | ||
| Crystallographic analysis of CD40 recognition and signaling by human TRAF2 | Q24675068 | ||
| Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40 | Q24676338 | ||
| Structural basis for self-association and receptor recognition of human TRAF2 | Q27617947 | ||
| TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway | Q28140039 | ||
| Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice | Q28140546 | ||
| Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain | Q28142613 | ||
| TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 | ||
| Bone resorption by osteoclasts | Q28145169 | ||
| TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor | Q28282051 | ||
| The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor | Q28285539 | ||
| ASK1 is essential for JNK/SAPK activation by TRAF2 | Q28285612 | ||
| The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily | Q28291317 | ||
| TRAF6 is a signal transducer for interleukin-1 | Q28291934 | ||
| Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region | Q28511583 | ||
| TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 | ||
| Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation | Q28584897 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Association of the p75 neurotrophin receptor with TRAF6 | Q28608954 | ||
| Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death | Q28609905 | ||
| Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function | Q29617462 | ||
| Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice | Q29618716 | ||
| New experimental approaches in retrovirus-mediated expression screening | Q32042655 | ||
| Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts | Q33939357 | ||
| Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice | Q35194925 | ||
| Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 | ||
| Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. | Q36301037 | ||
| PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase | Q37384701 | ||
| c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. | Q38352423 | ||
| An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-kappaB activation but is dispensable for c-Jun N-terminal kinase signaling | Q46630234 | ||
| Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. | Q52192178 | ||
| Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation | Q57675158 | ||
| c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling | Q58326943 | ||
| Unresponsiveness of MyD88-deficient mice to endotoxin | Q78093558 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1271-1280 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | The EMBO Journal | Q1278554 |
| P1476 | title | Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis | |
| P478 | volume | 20 |
| Q24292059 | A novel zinc finger protein that inhibits osteoclastogenesis and the function of tumor necrosis factor receptor-associated factor 6 |
| Q53364532 | A unique domain in RANK is required for Gab2 and PLCgamma2 binding to establish osteoclastogenic signals. |
| Q34825992 | A universal role for MyD88 in TLR/IL-1R-mediated signaling |
| Q36404190 | ADP-Ribosylation Factor 1 Regulates Proliferation, Migration, and Fusion in Early Stage of Osteoclast Differentiation |
| Q54699276 | Activation of the alpha3 integrin affects TRAF6 function in the IL-1 signaling pathway of CACO-2 epithelial cells. |
| Q34968667 | Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells |
| Q33711211 | Barley Seedling Extracts Inhibit RANKL-Induced Differentiation, Fusion, and Maturation of Osteoclasts in the Early-to-Late Stages of Osteoclastogenesis |
| Q33683266 | Basal autophagy prevents autoactivation or enhancement of inflammatory signals by targeting monomeric MyD88. |
| Q37982663 | Bisphosphonates: effects on osteoblast |
| Q33733731 | Blimp1-mediated repression of negative regulators is required for osteoclast differentiation |
| Q92704323 | Bone Regeneration, Reconstruction and Use of Osteogenic Cells; from Basic Knowledge, Animal Models to Clinical Trials |
| Q34541587 | Bone formation and resorption are both increased in experimental autoimmune arthritis. |
| Q64085953 | Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption |
| Q33701850 | CKIP-1 regulates macrophage proliferation by inhibiting TRAF6-mediated Akt activation |
| Q64236818 | Calcium-Phosphate Crystals Promote RANKL Expression via the Downregulation of DUSP1 |
| Q92422137 | Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review |
| Q34472121 | Cell adhesion signaling regulates RANK expression in osteoclast precursors |
| Q89553885 | Chaenomelis fructus inhibits osteoclast differentiation by suppressing NFATc1 expression and prevents ovariectomy-induced osteoporosis |
| Q37728405 | Cloning and characterization of DULP, a novel ubiquitin-like molecule from human dendritic cells |
| Q40279586 | Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling |
| Q39147426 | Critical Role of LTB4/BLT1 in IL-23-Induced Synovial Inflammation and Osteoclastogenesis via NF-κB. |
| Q37286240 | Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation |
| Q47131626 | Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation |
| Q37409392 | Cytokine-induced activation of mixed lineage kinase 3 requires TRAF2 and TRAF6. |
| Q36350166 | Cytoplasmic hnRNPK interacts with GSK3β and is essential for the osteoclast differentiation |
| Q48232446 | Development of intestinal M cells and follicle-associated epithelium is regulated by TRAF6-mediated NF-κB signaling. |
| Q47940565 | Dihydroartemisinin, an Anti-Malaria Drug, Suppresses Estrogen Deficiency-Induced Osteoporosis, Osteoclast Formation, and RANKL-Induced Signaling Pathways |
| Q36739991 | Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis |
| Q35819694 | Effects of Inositol 1,4,5-triphosphate on Osteoclast Differentiation in RANKL-induced Osteoclastogenesis |
| Q34346080 | Emerging complexity of protein ubiquitination in the NF-κB pathway |
| Q40120415 | Eriodictyol Inhibits RANKL-Induced Osteoclast Formation and Function Via Inhibition of NFATc1 Activity. |
| Q93206720 | Evodiamine inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice |
| Q37816941 | Expanding role of ubiquitination in NF-κB signaling |
| Q24796088 | Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation |
| Q34014506 | FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner |
| Q38541335 | Focus on the p38 MAPK signaling pathway in bone development and maintenance |
| Q35079256 | Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members |
| Q35899430 | Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. |
| Q48368263 | Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of Osteoclastogenesis. |
| Q37689232 | Heme oxygenase-1 (HO-1)/carbon monoxide (CO) axis suppresses RANKL-induced osteoclastic differentiation by inhibiting redox-sensitive NF-κB activation |
| Q35784954 | Herpesvirus saimiri STP-A oncoprotein utilizes Src family protein tyrosine kinase and tumor necrosis factor receptor-associated factors to elicit cellular signal transduction |
| Q33574123 | Hexane-Soluble Fraction of the Common Fig, Ficus carica, Inhibits Osteoclast Differentiation in Murine Bone Marrow-Derived Macrophages and RAW 264.7 Cells |
| Q28505337 | Hsp70 inhibits lipopolysaccharide-induced NF-kappaB activation by interacting with TRAF6 and inhibiting its ubiquitination |
| Q62269692 | IL-1α (− 889) promoter polymorphism is a risk factor for osteomyelitis |
| Q84033281 | Identification and characterization of anti-osteoclastogenic peptides derived from the cytoplasmic tail of receptor activator of nuclear factor kappa B |
| Q28207396 | Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase-1 (IRAK-1) in IL-1 receptor signaling |
| Q29618116 | Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts |
| Q39343563 | Inflammatory osteolysis: a conspiracy against bone |
| Q53250109 | Inhibitory effects of triptolide on titanium particle-induced osteolysis and receptor activator of nuclear factor-κB ligand-mediated osteoclast differentiation. |
| Q28484592 | Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer |
| Q38135805 | Interaction between the immune system and bone metabolism: an emerging field of osteoimmunology |
| Q37829690 | Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications |
| Q83350762 | Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis |
| Q24658087 | Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of IkappaBalpha kinase |
| Q33269870 | Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus |
| Q36749163 | Investigation of proteome changes in osteoclastogenesis in low serum culture system using quantitative proteomics. |
| Q39018581 | Involvement of redox balance in in vitro osteoclast formation of RAW 264.7 macrophage cells in response to LPS. |
| Q47140180 | Kaempferide Prevents Titanium Particle Induced Osteolysis by Suppressing JNK Activation during Osteoclast Formation |
| Q56897808 | Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling |
| Q36437727 | Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and Facilitates Runx2-mediated Osteoblastogenesis |
| Q46196784 | Lipoproteins are an important bacterial component responsible for bone destruction through the induction of osteoclast differentiation and activation. |
| Q40145765 | Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades. |
| Q47804232 | MEK is a key modulator for TLR5-induced interleukin-8 and MIP3alpha gene expression in non-transformed human colonic epithelial cells |
| Q36073894 | Mechanistic insight into osteoclast differentiation in osteoimmunology |
| Q40663935 | Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function |
| Q42642070 | Molecular biology of bone remodelling |
| Q38074961 | Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts |
| Q35157702 | Molecular mechanisms underlying osteoclast formation and activation |
| Q36585134 | Molecular regulation of osteoclast activity |
| Q35416974 | Mutant p62P392L stimulation of osteoclast differentiation in Paget's disease of bone |
| Q49025968 | MyD88S, a splice variant of MyD88, differentially modulates NF-kappaB- and AP-1-dependent gene expression |
| Q36725293 | NF-kappaB activation in development and progression of cancer |
| Q24322734 | NF-kappaB activator Act1 associates with IL-1/Toll pathway adaptor molecule TRAF6 |
| Q26822516 | NF-κB, the first quarter-century: remarkable progress and outstanding questions |
| Q81019001 | Neurotrophin signaling through the p75 receptor is deficient in traf6-/- mice |
| Q37987556 | New regulation mechanisms of osteoclast differentiation |
| Q37720087 | Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation in vitro |
| Q34530518 | Noncanonical G-protein-dependent modulation of osteoclast differentiation and bone resorption mediated by Pasteurella multocida toxin |
| Q33838967 | Osteoblast Role in Rheumatic Diseases. |
| Q39251652 | Osteoblast role in osteoarthritis pathogenesis |
| Q30482448 | Osteoblasts induce Ca2+ oscillation-independent NFATc1 activation during osteoclastogenesis |
| Q29547556 | Osteoclast differentiation and activation |
| Q36402845 | Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis |
| Q90224356 | Osteoclast-Like Cells in Aneurysmal Disease Exhibit an Enhanced Proteolytic Phenotype |
| Q37808649 | Osteoclastogenesis and arthritis |
| Q37118763 | Osteoclasts - the innate immune cells of the bone |
| Q37489600 | Osteoclasts and the immune system |
| Q88248494 | Osteoimmunology |
| Q47944184 | Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. |
| Q37544448 | Osteoimmunology: crosstalk between the immune and bone systems |
| Q38960189 | Osteoimmunology: memorandum for rheumatologists. |
| Q28294477 | Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems |
| Q89998406 | Osthole-loaded N-octyl-O-sulfonyl chitosan micelles (NSC-OST) inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in rats |
| Q93102422 | PIP5k1β controls bone homeostasis through modulating both osteoclast and osteoblast differentiation |
| Q36328818 | PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling pathways |
| Q34424327 | PKCβ positively regulates RANKL-induced osteoclastogenesis by inactivating GSK-3β. |
| Q40617973 | PU.1 target genes undergo Tet2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation |
| Q49891124 | Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis |
| Q48206811 | Picroside II Inhibits RANKL-Mediated Osteoclastogenesis by Attenuating the NF-κB and MAPKs Signaling Pathway In Vitro and Prevents Bone Loss in Lipopolysaccharide Treatment Mice |
| Q60928140 | Propofol promotes osteoclastic bone resorption by increasing DC-STAMP expression |
| Q51355256 | Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo. |
| Q33391408 | Protective protein/cathepsin A down-regulates osteoclastogenesis by associating with and degrading NF-kappaB p50/p65. |
| Q41462303 | Proteomic Analysis of Estrogen-Mediated Signal Transduction in Osteoclasts Formation |
| Q28486296 | Pyrroloquinoline quinine inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos in mouse bone marrow cells and inhibits wear particle-induced osteolysis in mice |
| Q41107411 | RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. |
| Q39761712 | RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis |
| Q89967663 | RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies |
| Q35800463 | RNA therapeutics targeting osteoclast-mediated excessive bone resorption |
| Q40343549 | Rac1 GTPase regulates osteoclast differentiation through TRANCE-induced NF-kappa B activation |
| Q34611297 | Reaching a genetic and molecular understanding of skeletal development |
| Q40633180 | Receptor Activator of NF-κB Ligand Stimulates Recruitment of SHP-1 to the Complex Containing TNFR-Associated Factor 6 That Regulates Osteoclastogenesis |
| Q24537518 | Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6 |
| Q39595473 | Regulation of RANKL-induced osteoclastogenesis by TGF-β through molecular interaction between Smad3 and Traf6. |
| Q40323778 | Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. |
| Q46174778 | Regulation of selective PPARγ modulators in the differentiation of osteoclasts |
| Q36371153 | Regulation of the subcellular localization of tumor necrosis factor receptor-associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling |
| Q39221657 | Role of FK506 binding protein 5 (FKBP5) in osteoclast differentiation |
| Q34963016 | Role of RANKL and RANK in bone loss and arthritis. |
| Q35165886 | Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications |
| Q34886943 | Role of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease |
| Q36961046 | Roles of TRAF6 in CD40 signaling |
| Q33620139 | Roles of the TRAF6 and Pellino E3 ligases in MyD88 and RANKL signaling |
| Q49950374 | STAC2 negatively regulates osteoclast formation by targeting the RANK signaling complex |
| Q36534061 | Selective Regulation of MAPK Signaling Mediates RANKL-dependent Osteoclast Differentiation |
| Q35126799 | Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts |
| Q26766637 | Signaling Pathways in Osteoclast Differentiation |
| Q34731222 | Signaling crosstalk between RANKL and interferons in osteoclast differentiation |
| Q35587493 | Signaling pathways in osteogenesis and osteoclastogenesis: Lessons from cranial sutures and applications to regenerative medicine. |
| Q33693806 | Signaling to NF-kappaB: regulation by ubiquitination |
| Q24319108 | Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling |
| Q35745300 | Stauntonia hexaphylla (Lardizabalaceae) leaf methanol extract inhibits osteoclastogenesis and bone resorption activity via proteasome-mediated degradation of c-Fos protein and suppression of NFATc1 expression |
| Q92610634 | Streptococcus pneumoniae triggers hierarchical autophagy through reprogramming of LAPosome-like vesicles via NDP52-delocalization |
| Q24292181 | T2BP, a novel TRAF2 binding protein, can activate NF-kappaB and AP-1 without TNF stimulation |
| Q34472774 | TAB2 is essential for prevention of apoptosis in fetal liver but not for interleukin-1 signaling |
| Q24324222 | TAK1-dependent signaling requires functional interaction with TAB2/TAB3 |
| Q74434100 | TIRAP: how Toll receptors fraternize |
| Q34311797 | TRAF-6 dependent signaling pathway is essential for TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation |
| Q28505658 | TRAF6 Is a Critical Factor for Dendritic Cell Maturation and Development |
| Q30159856 | TRAF6 activation of PI 3-kinase-dependent cytoskeletal changes is cooperative with Ras and is mediated by an interaction with cytoplasmic Src. |
| Q37052635 | TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta |
| Q40325218 | TRAF6 regulates cell fate decisions by inducing caspase 8-dependent apoptosis and the activation of NF-kappaB. |
| Q24530773 | TRAF6-deficient mice display hypohidrotic ectodermal dysplasia |
| Q61443238 | TRAIL inhibits RANK signaling and suppresses osteoclast activation via inhibiting lipid raft assembly and TRAF6 recruitment |
| Q83061700 | Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis |
| Q41684447 | The Beneficial Effect of Praeruptorin C on Osteoporotic Bone in Ovariectomized Mice via Suppression of Osteoclast Formation and Bone Resorption |
| Q60932819 | The Dual Role of Oat Bran Water Extract in Bone Homeostasis Through the Regulation of Osteoclastogenesis and Osteoblast Differentiation |
| Q41062466 | The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling |
| Q24301337 | The LIM protein Ajuba influences interleukin-1-induced NF-kappaB activation by affecting the assembly and activity of the protein kinase Czeta/p62/TRAF6 signaling complex |
| Q64102143 | The RANKL-RANK Axis: A Bone to Thymus Round Trip |
| Q24654977 | The RING domain and first zinc finger of TRAF6 coordinate signaling by interleukin-1, lipopolysaccharide, and RANKL |
| Q42148237 | The RING domain of TRAF2 plays an essential role in the inhibition of TNFalpha-induced cell death but not in the activation of NF-kappaB. |
| Q27677993 | The Shigella flexneri effector OspI deamidates UBC13 to dampen the inflammatory response |
| Q38694527 | The Simultaneous Inhibitory Effect of Niclosamide on RANKL-Induced Osteoclast Formation and Osteoblast Differentiation |
| Q51040187 | The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. |
| Q34108110 | The emerging field of osteoimmunology |
| Q55117611 | Therapeutic and Preventive Effects of Osteoclastogenesis Inhibitory Factor on Osteolysis, Proliferation of Mammary Tumor Cell and Induction of Cancer Stem Cells in the Bone Microenvironment. |
| Q37825905 | Therapeutic targeting of osteoclast function and pathways. |
| Q28586618 | Traf6 is essential for murine tooth cusp morphogenesis |
| Q33996260 | Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis in mice and does not associate with atherosclerosis in humans |
| Q37327225 | Ubiquitin in NF-kappaB signaling. |
| Q36819396 | Ubiquitin-mediated activation of TAK1 and IKK. |
| Q39318861 | Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. |
| Q90599354 | Umbelliferone Prevents Lipopolysaccharide-Induced Bone Loss and Suppresses RANKL-Induced Osteoclastogenesis by Attenuating Akt-c-Fos-NFATc1 Signaling |
| Q90294419 | Various roles of heme oxygenase-1 in response of bone marrow macrophages to RANKL and in the early stage of osteoclastogenesis |
| Q37836495 | Why TNF-α inhibition is not sufficient to avoid juxta-articular erosions in chronic arthritis? |
| Q35034056 | c-Jun N-terminal Kinase 2 Regulates Multiple Receptor Tyrosine Kinase Pathways in Mouse Mammary Tumor Growth and Metastasis |
| Q39249506 | cIAP1/2 negatively regulate RANKL-induced osteoclastogenesis through the inhibition of NFATc1 expression |
| Q40103209 | miR-146a-Traf6 regulatory axis controls autoimmunity and myelopoiesis, but is dispensable for hematopoietic stem cell homeostasis and tumor suppression |
| Q38807300 | uPA Attenuated LPS-induced Inflammatory Osteoclastogenesis through the Plasmin/PAR-1/Ca(2+)/CaMKK/AMPK Axis |
Search more.